Adult stem cells may serve as powerful cellular vehicles to deliver therapeutic genes for cancer therapy. In such applications, effective and safe transduction to load stem cells with genes of interest is essential. To examine whether baculovirus can be used to fulfill this task, we tested a range of baculoviral vectors in human bone marrow mesenchymal stem cells (MSCs). A vector using the human cytomegalovirus immediate-early gene promoter to drive transgene expression and the woodchuck hepatitis virus posttranscriptional regulatory element to enhance translation was able to transduce MSCs with efficiency close to 80%. Following the observation that baculoviral transduction did not significantly affect surface marker expression of the stem cells, we tested the feasibility of using baculovirus-transduced MSCs for targeted cancer therapy. We transduced cells with a baculoviral vector harboring the herpes simplex virus thymidine kinase gene, and performed tail vein injection of the transduced cells into mice preinoculated subcutaneously with human U87 glioma cells. After ganciclovir prodrug injection, we observed inhibition of tumor growth and significantly prolonged survival of tumor-inoculated animals. Our findings suggest that baculoviral transduction of MSCs is an attractive option to generate targeting vehicles for systemic cancer therapy.
Introduction
The mesenchymal stroma is a determining factor in controlling tumor growth. Being progenitors of stromal cells and fibroblasts, bone marrow mesenchymal stem cells (MSCs) exhibit tropism for tumors by responding to inflammatory mediators secreted from tumor cells and migrating to tumor tissues. [1] [2] [3] With genetic engineering to introduce therapeutic genes into MSCs, the cells have been exploited for delivering gene products to main tumor mass, as well as to tumors distant from an MSC injection site, [4] [5] [6] [7] [8] thus allowing the development of therapeutic strategies for active targeting to both primary and metastatic tumors.
Many studies used integrating viruses, such as lentivirus or retrovirus, to instigate stable expression of therapeutic transgenes in MSCs. [9] [10] [11] These viruses preferentially integrate into transcriptionally active regions of genomes, raising concerns over insertional mutagenesis, oncogene activation and cellular transformation. 12 Non-integrating adenovirus and adeno-associated virus have been successfully used for transduction of MSCs. 6, 7, [13] [14] [15] These are infectious human viruses. A common concern associated with the use of human viral vectors is the preexisting immunity directed against them in the vast majority of the human population. Indeed, specific antibodies against adenoviruses are detectable in 97% of individuals and those against AAV2 in 35-80% of individuals, depending on age group and geographic location. 16 A question that remains unanswered is whether such adaptive immunity would lead to undesired rejection response to the MSCs transduced by adenovirus or adeno-associated virus.
Baculoviral vectors, derived from an insect virus Autographa californica multiple nucleopolyhedrovirus, are emerging as a novel class of vectors for gene delivery in recent years. This insect DNA virus has the ability to enter mammalian cells without replicating or causing toxicity to the transduced cell. Its high cloning capacity allows accommodation and delivery of large functional genes or multiple genes. Baculoviral vectors have been successfully used for transduction of human bone marrow MSCs. [17] [18] [19] After transplantation of baculovirustransduced MSCs into allogeneic animals, there was no obvious cell clearance, as judged by the persistence of transplanted cells and absence of CD8 þ T cells infiltration, 19 suggesting the potential and safety of in vivo applications of baculovirus-transduced MSCs for cell-based gene therapy. In an effort to test tissue engineering by gene delivery, MSCs genetically modified ex vivo by baculoviral vectors were able to induce ectopic bone formation and repair osteochondral defects in animals. 20 In this study, we explored the possibility of using baculovirus-transduced, ex vivo genetically engineered MSCs for cancer therapy. We were particularly interested in whether systemic delivery of these MSCs through intravenous injection would be functional in cancer therapy.
Materials and methods

Cells
Human bone marrow MSCs were obtained from Lonza Cologne AG (Koeln, Germany) and cultured in MSCGM hMSC basal medium (Lonza). These cells were harvested from normal human bone marrow and tested for purity by flow cytometry and for their ability to differentiate into osteogenic, chondrogenic and adipogenic lineages. Cells are positive for CD105, CD166, CD29 and CD44 and negative for CD14, CD34 and CD45. MSCs between passages 7 and 10 were used in the current study.
Human glioblastoma U87MG cell line was purchased from American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, 2 mM glutamine and 0.1 mM nonessential amino acids. The stable U87 cell clone expressing luciferase gene (U87-luc) was generated as described previously. 21 Briefly, U87 cells were seeded in a six-well plate at a density of 5 Â 10 5 cells per well and transfected with pRC-CMV2-luc plasmid using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After 1 day, transfected cells were transferred to a 100-mm cellculture dish and 1 mg ml À1 geneticin was added to the medium to select the resistant cells. After 1 week's selection, resistant cells were seeded in a 96-well plate at density of 1 cell per well to form colonies. A total of 10 colonies were selected and expanded, and the luciferase activity was measured using an assay kit from Promega (Madison, WI, USA) in a single-tube luminometer (Berthold Lumat LB 9507, Bad Wildbad, Germany). A U87-luc clone with the highest luciferase activity was chosen and maintained with 500 mg ml À1 geneticin.
Baculovirus preparation and cell transduction Baculoviral vectors with the enhanced green fluorescent protein (eGFP) reporter gene were constructed in our previous study. [22] [23] [24] The transfer plasmid pFastBac1 (Invitrogen) was used to generate recombinant baculoviruses with different expression cassettes. To generate the recombinant baculovirus vector containing the herpes simplex virus thymidine kinase (HSVtk) gene, the HSVtk gene with flanking EcoRI and XhoI sites was obtained through PCR amplification from the pORF-HSVtk plasmid (InvivoGen, San Diego, CA, USA) using forward primer 5 0 -GTGAACCGTCAGATCGAATTCCTGAGA TCACCGGCGAAGGA-3 0 and reverse primer 5 0 -CCAG AGGTTGATTATCGCTCGAGTCAGTTAGCCTCCC CCATCT-3 0 , and used to replace the eGFP gene in our CMV-W vector. 21 BacPAK6, a baculoviral vector without a mammalian gene expression cassette, was purchased from Clontech (Mountain View, CA, USA).
Viruses were produced and propagated in Sf9 insect cells according to the manual of Bac-to-Bac baculovirus expression system (Invitrogen). Budded viruses in the insect cell-culture medium were centrifuged at 2000 g for 10 min to remove cell debris, and concentrated by a second round of centrifugation at 28 000 g for 60 min. Viral pellets were resuspended in 0.1 M phosphatebuffered saline (PBS) and their infectious titers (plaqueforming unit, pfu) were determined by plaque assay on Sf9 cells.
For baculoviral transduction, cells were seeded in a 12-well plate at a density of 5 Â 10 4 cells per well, transduced in suspension in 500 ml MSCGM Basal medium at an multiplicity of infection of 100 and left to incubate overnight. This is followed by an addition of 500 ml of the medium to each well the next day, and a full change of the medium on day 2 posttransduction if transduced cells were cultivated for longer than 2 days.
FACS analysis and western blotting
When fluorescence-activated cell sorting (FACS) analysis was used to evaluate transduction efficiency, baculovirustransduced cells were trypsinized to single cells and collected in PBS before analysis with the FACSCalibur flow cytometer (BD Biosciences, San Diego, CA, USA). To examine effects of baculoviral transduction on surface marker expression, the cell pellet was resuspended and blocked in 1% bovine serum albumin/PBS for 30 min. Samples were incubated for an hour with phycoerythrinconjugated primary monoclonal antibodies, including anti-CD34, anit-CD45, anti-CD73 and anti-CD90 from BD Pharmingen (San Diego, CA, USA) and anti-CD105 from eBioscience (San Diego, CA, USA). After two washes with PBS, samples were resuspended in PBS for FACS analysis.
Western blotting was used for the analysis of HSVtk gene expression after baculoviral transduction. MSCs transduced with the HSVtk baculoviral vector were lysed on days 3 and 8 posttransduction. Cell lysates were centrifuged at 10 000 g for 10 min at 4 1C. Samples were mixed with one quarter volume of 4 Â NuPAGE sample buffer (Invitrogen) and one-tenth volume of b-mercaptoethanol, heated at 70 1C for 10 min and separated on 4-12% Bis-Tris gel with MES running buffer. Electroblotting was performed using the iBlot dry blotting system (Invitrogen). The membrane was blocked in 5% nonfat milk in tris-buffered saline tween-20 for an hour, and incubated overnight with rabbit anti-HSVtk primary antibody (1:100; kindly provided by Dr William Summer, Yale University), and for 1 h with mouse monoclonal b-actin primary antibody (1:1000; Sigma, St Louis, MO, USA). After washing, the membrane was incubated with horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG for 1 h. Protein bands were visualized on an X-Ray film after a 10 s exposure.
In vitro cytotoxicity assay
Mesenchymal stem cells were transduced with the HSVtk baculoviral vector. Transduced MSCs were trypsinized and mixed with U87 glioma cells at different ratios 3 or 8 days after transduction. The mixed cells were seeded on 96-well plates (1000 cells per well) and cultivated in U87 cell-culture medium. In some experiments, untransduced MSCs mixed with U87 cells were included for comparison. Ganciclovir (GCV) was added at concentration of 0, 10, 100 or 1000 mM. After 5 days of GCV treatment, CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) was performed to evaluate cytotoxicity.
Animal studies in vivo
Adult female Balb/c athymic, immunoincompetent nude mice (weight 20 g; aged 6-8 weeks) were used. A xenograft tumor model was established by inoculating 1 Â 10 6 U87 human glioblastoma cells expressing luciferase reporter gene (U87-luc) subcutaneously into the root of the right thigh of the mouse. On day 6 after tumor inoculation, animals were divided into four groups for tail vein injection of sample solutions (n ¼ 9-10 per group): PBS, 1 Â 10 6 MSCs in PBS, 1 Â 10 6 MSCs transduced with a baculoviral vector containing the eGFP gene in PBS and 1 Â 10 6 MSCs transduced with the HSVtk baculoviral vector in PBS. The cells were transduced with baculoviral vectors 1 day before the tail vein injection. A volume of 200 ml of the sample solution was injected into the tail vein. Animals were then intraperitoneally administered with 50 mg ml À1 of GCV from day 11 to 15 and day 18 to 22 after tumor inoculation. To monitor bioluminescent singles of U87-luc cells, isoflurane gas-anesthetized animals were injected intraperitoneally with 200 ml of D-luciferin (5 mg ml À1 , Promega) in PBS and placed on a warmed stage inside the camera box of the IVIS imaging system (Xenogen, Alameda, CA, USA) coupled with cool CCD camera. Luminescent images were taken 20 min after luciferin injection as a 60-s acquisition. The detected light emitted from U87-luc cells was digitized and electronically displayed as a pseudocolor overlay onto a grayscale image of the animal. Images and measurements of luminescent signals were acquired and analyzed with the Xenogen living imaging software v2.5 and quantified as photons per s. Surviving animals were killed at day 60 and the tumor size was measured. Tumor size was measured by a caliper and calculated as 0.5 Â width 2 Â length and shown as cm 3 . All handling and care of animals was carried out according to the Guidelines on the Care and Use of Animals for Scientific Purposes issued by the National Advisory Committee for Laboratory Animal Research, Singapore.
Statistical analysis
All data are presented as mean±s.d. The statistical significance of differences was determined by the twofactor analysis of variance (ANOVA) with replication followed by Holm-Sidak post hoc analysis or by unpaired Student's t-test. The statistical analysis of survival data was performed using the log-rank test followed by HolmSidak method for pairwise multiple comparison tests.
A P-value of o0.05 was considered to be statistically significant.
Results
Baculoviral vectors typically mediate transient transduction, and the transgene expression may extinguish within days to weeks. To select a proper baculoviral vector that can mediate transgene expression in MSCs long enough for cancer therapy, we tested six different baculoviral vectors developed in our previous studies. [22] [23] [24] These vectors harbor an eGFP reporter gene under control of different promoters and virus-derived transcriptional regulatory elements ( Figure 1a) . As estimated by the percentage of eGFP-positive cells on day 2 after transduction, the vectors with the viral cytomegalovirus (CMV) promoter were more efficient than those with a cellular housekeeping EF1a promoter (Figure 1b) . One of the vectors accommodating both the CMV promoter and the woodchuck hepatitis virus posttranscriptional regulatory element, named BV-CMV-W, provided the highest transduction efficiency, with close to 80% of MSCs being transduced (Figure 1b) . This efficiency was much higher than that provided by the baculoviral vector accommodating the CMV promoter alone, showing that woodchuck hepatitis virus posttranscriptional regulatory element can enhance CMV promoter-mediated gene expression in MSCs. When tested in a time course experiment, BV-CMV-W was able to maintain transgene expression in more than 50% of cells for at least 2 weeks, with the percentage of eGFP-positive cells falling to 20% on day 21 and to 5% on day 30 (Figure 1c) . The mean fluorescence intensity of the eGFP-positive cells in this experiment ranged from 1350 in the first week to 500 on day 30.
To investigate whether baculoviral transduction altered the stem cell identity of MSCs, cell surface markers were analyzed after mock-transduction or transduction with BacPAK6, a baculoviral vector without a mammalian gene expression cassette. At 24 h posttransduction, cells were collected for immunofluorescence labeling and FACS analysis according to a previous study. 25 Consistent with published reports, 25, 26 mock-transduced MSCs stained positive with CD73, CD90 and CD105, but lacked expression of CD34 and CD45. Baculoviral transduction did not obviously alter the expression of these surface markers, except causing a slight increase in CD73 expression (Figure 2 ). These findings suggest that baculoviral transduction does not affect MSC characteristics.
The accessibility of MSCs for baculovirus-mediated genetic manipulation promotes us to test whether these transduced cells can be used for targeted cancer therapy. To that end, we constructed a baculoviral vector accommodating the HSVtk suicide gene under the control of the CMV promoter and woodchuck hepatitis virus posttranscriptional regulatory element. HSVtk expression followed by the prodrug GCV treatment is commonly used in cancer suicide gene therapy, as HSVtk-phosphorylated GCV has been shown to display bystander effect by diffusing to nearby cells, hence killing them. 27 Figure 3a confirmed that transduction using our HSVtk baculoviral vector resulted in detectable expression of the HSVtk protein in MSCs. To test the bystander effect, we prepared cell mixtures by mixing the HSVtk-expressing MSCs and human U87 glioma cells at different ratios from no MSCs to 100% MSCs on either day 3 or 8 posttransduction, and cultured them in medium containing 10 mM GCV for 5 days before performing a cell viability assay (Figure 3b ). GCV at 10 mM did not induce any cell death in U87 cells in the absence of HSVtkexpressing MSCs (no MSCs). This concentration of GCV killed 40% of HSVtk-expressing MSCs in the wells of 100% MSCs transduced 3 days before. When HSVtkexpressing MSCs in the wells of 100% MSCs transduced 8 days before were subjected to the GCV treatment, the rate of cell death increased to 80%, probably because of greater accumulation of phosphorylated GCV. In 90:10 cocultures of U87 cells and HSVtk-expressing MSCs, 40 and 70% of cells died, respectively, in the presence of HSVtk-expressing MSCs transduced 3 and 8 days before. These results show clearly that only a small number of HSVtk-expressing MSCs would be enough to result in a bystander effect. After mixing U87 cells with HSVtkexpressing MSCs at a ratio of 50:50, we observed a killing effect of B80% at a GCV concentration of 10 mM. We further investigated GCV dose-dependent cytotoxic effects and observed that increases in GCV concentration to 100 and 1000 mM augmented cell-killing effects to X90% (Figure 3c ). However, high concentrations of GCV, especially at 1000 mM, could cause obvious cytotoxicity even when nontransduced MSCs were used (Figure 3c) , indicating a nonspecific effect of unphosphorylated GCV at a high concentration.
Having tested the efficiency of baculovirus-transduced, HSVtk-expressing MSCs in eliminating U87 cells in vitro, we next examined the in vivo efficacy of these cells. We established tumor xenografts in nude mice by subcutaneous inoculation of U87 cells stably expressing luciferase (U87-luc cells). After 6 days, the tumor-inoculated mice were divided into four groups for tail vein injection of PBS, MSCs in PBS, MSCs transduced with a baculoviral vector containing the eGFP gene in PBS (MSC-eGFP) or MSCs transduced with the HSVtk baculoviral vector in PBS (MSC-tk). After GCV injection, tumor growth was monitored by bioluminescent imaging of U87-luc cells using the IVIS imaging system. As shown in Figure 4a , the bioluminescence intensities, indicative of the tumor volume, show that the tail vein injection of MSC-tk cells produced more pronounced inhibitory effects on tumor growth than injection of other control cells or PBS. This correlated well with tumor size measured in surviving animals at day 60 after tumor inoculation, the longest period investigated (Figures 4b and c) . Attributed to the inhibitory effect on tumor growth provided by the MSC-tk/GCV regime, the survival of the tumor-inoculated mice in this group was significantly prolonged (Figure 4d) . At day 60, only 1 mouse out of 10 died in this group, whereas 9 out of 10 animals in the PBS control group had died (P ¼ 0.000194). In the two control groups, MSC and MSC-eGFP, B60% of the animals died by day 60 (P ¼ 0.445). The P-value on the difference between the MSC group and the MSC-tk group was 0.00680, and that between the MSC-eGFP group and the MSC-tk group was 0.0140. Thus, the MSC-tk/GCV regime was powerful enough to slow down in vivo growth of glioma cells after systemic MSC injection.
Discussion
Cancer invasion and metastasis is one of the major obstacles to cancer treatment and the principal cause of poor prognosis in patients with cancer. Taking full advantage of the intrinsic tropism for tumors of adult stem cells, especially MSCs and neural stem cells, many laboratories have used these cells for cancer therapy in animal models and showed that stem cells that home in on tumors are able to deliver therapeutic genes to tumor sites distant from a stem cell injection site.
Findings from our in vivo animal study suggest that intravenously injected MSCs were able to deliver the HSVtk suicide gene to tumors at a remote site. Tumor growth was inhibited on introduction of GCV, thus prolonging the survival of tumor-bearing animals. The prolonged survival in the group treated with MSCs containing the HSVtk gene over the group treated with MSCs containing a nontherapeutic eGFP gene is the evidence of the HSVtk effect, whereas the lack of significant difference in survival between the MSC-eGFP group and the group injected with unmodified MSCs indicates that baculoviral transduction alone has no effects on tumor growth. When compared with the PBS group, animals injected with MSCs that do not contain a therapeutic gene, that is, those in the MSC-eGFP group and the unmodified MSC group, seemed to prolong the survival of U87 glioma-bearing animals. This anti-glioma effect of MSCs observed in the current study is consistent with the report by Nakamura K et al., 6 who showed the growth suppression of 9L glioma by intratumoral injection of MSCs in the rat brain, and attested the increased survival of these 9L glioma-bearing animals. As MSCs produce several neurotrophic factors that can induce the differentiation and growth inhibition of glioma cells, the authors have suggested that the soluble factors released from MSCs may be the mediators involved in the antitumor mechanism of MSCs. Similarly, growth suppression of lung cancer cells by soluble factors released from MSCs has been shown previously. 28, 29 In using stem cells as delivery vectors for cancer therapy, it is essential that these cells can be genetically modified in a safe and effective way to carry therapeutic payloads of interest over the period of time crucial to the therapy. In the current study, we showed for the first time that baculoviral vectors can be used to fulfill this task to generate genetically modified MSCs for systemic cancer therapy in an animal model.
One characteristic of baculoviral transduction is that transgenes are usually not integrated into the genome of host mammalian cells. Only with antibiotic selection could stable cells expressing GFP be isolated after baculovirus transduction, 30, 31 suggesting that the frequency of spontaneous chromosomal integration of delivered DNA sequences without positive selection, if any, would be very low in transduced cells. Thus, baculoviral vectors appear not to disturb host genome and should pose much less risk of insertional mutagenesis.
Another important advantage of using baculovirus for genetic modification of MSCs is the absence of preexisting antivirus immunity in humans. As revealed by a comparison study, the prevalence of neutralizing antibodies against adenovirus type 5 was 65% in human serum samples (n ¼ 13/20), whereas none of the serum samples (n ¼ 21) was positive for baculovirus-neutralizing antibodies. 32 Likewise, preexisting adenovirus-specific T cells were detectable, but there were no preexisting baculovirus-specific T cells in humans. 32 Baculoviral transduction has been shown by Ho YC et al. 17 to retain the proliferation capacity of bone marrow MSCs and these transduced cells can still differentiate down the þ þ Po0.01 and þ þ þ Po0.001 between cells mixed on day 3 and day 8 posttransduction by Student's t-test. In c, ANOVA analysis revealed that the differences between the presence of MSC-tk and the presence of nontransduced MSCs were significant at all three tested GCV concentrations (Po0.001), regardless of whether the cells were mixed with U87 on day 3 or 8 posttransduction.
adipogenic lineage. A recent paper from the same laboratory has further shown that baculovirus transduction has no effect on the immunological properties on MSCs, especially their ability to evade immune recognition, in immunocompetent rats. 19 Putting all these together, we believe that baculovirus will be useful as a safe and efficient vector for genetic modification of MSCs for downstream medical applications of these cells.
Apart from the HSVtk/GCV gene-directed enzyme prodrug therapy system, another system commonly used with MSCs is the cytosine deaminase (CD)/5-fluorocytosine (5-FC) system. The therapeutic potential of using MSCs as a tumor trophic cellular vehicle for the CD gene has been shown in human prostrate and colon tumor models. 33, 34 In the CD/5-FC system, the nontoxic prodrug 5-FC is deaminated by CD and converted into 5-fluorouracil, which gets further processed in the cells into cytotoxic forms that interfere with RNA or DNA synthesis. Some studies have in fact shown the CD/5-FC system to be more potent than HSVtk/GCV system in in vitro eradication of human colorectal carcinoma, hepatocellular carcinoma and even Epstein-Barr viruspositive B lymphocytes; [35] [36] [37] others have combined the two systems and reported an enhanced antitumor activity in vitro and in vivo. [38] [39] [40] All these previous studies in the field seem to indicate the success of gene-directed enzyme prodrug therapy systems in eradicating a large range of tumor types, highlighting thus, the broad usage of these gene-directed enzyme prodrug therapy systems. It will be interesting to investigate whether baculovirus-mediated genetic modification of MSCs is able to produce a good therapeutic effect on cancer treatment when coupled with the CD/5-fluorouracil system or with both the CD/5-fluorouracil and the HSVtk/GCV systems. Other possibilities for future work include testing our baculovirusmediated gene modification in other gene-directed enzyme prodrug therapy models such as the P450 prodrugactivation gene therapy, and with other tumor trophic cellular vehicles such as the neural stem cells.
In conclusion, baculoviral transduction has been shown in the present study to be an attractive option for genetic modification of bone marrow MSCs, a powerful cellular vector for intratumoral gene delivery. Particularly, as baculovirus-transduced MSCs can be recruited to tumors after systemic injection, these cells are promising targeting vehicles for treatment of invasive and metastatic tumors.
